Join us.

We’re working to create a just society and preserve a healthy environment for future generations. Donate today to help.

Donate

Late last month, the White House Office of Information and Regulatory Affairs (OIRA) posted on its website a document called Agency Checklist: Regulatory Impact Analysis, which, according to the document, is intended to assist federal regulatory agencies with Executive Order 12866-required cost-benefit analyses (CBAs). Such analyses have become a standard, if fatally flawed, stage in the regulatory process.  Substantively speaking, OIRA’s document contains nothing new or particularly earth-shattering—instead, it is merely a checklist of some of the requirements for CBAs established by Executive Order 12866 and Circular A-4, a document issued by OIRA in 2003 to provide agencies with comprehensive guidance on how to produce CBAs.

Significantly, though, Executive Order 12866 also establishes several responsibilities for OIRA to guide its participation in the regulatory review process. As CPR’s previous work has made abundantly clear, however, OIRA fails to live up to many of these responsibilities. So, in the spirit of OIRA’s Agency Checklist, but without endorsing the institutions of CBA or centralized regulatory review, I modestly propose the following OIRA Checklist to assist it when it carries out its responsibilities in the centralized regulatory review process:

Simply stated, OIRA is in apparent violation of presidential Executive Orders. Worse, it violates those Orders in service of blocking, delaying and watering down efforts by regulatory agencies to pursue their statutory mandate to protect health, safety and the environment. That’s been the case for years, and sadly, the Obama Administration is missing the chance to reverse the trend.

The Agency Checklist very much fits the mold of the Administration’s Open Government Directive, which imposed a series of transparency requirements on regulatory agencies, but ignored the massive transparency problems at OIRA. In either case, bigger improvements in the regulatory process would be achieved if the focus were placed where it is most needed: on OIRA. If OIRA is really that concerned with improving the quality of the regulatory review process, it should start by addressing its own shortcomings.